We are live on ! Find out more
BIOS

BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS

Delisted

BIOS was delisted on the 6th of October, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in BioPlus Acquisition Corp. Class A Ordinary Shares in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 30 → 0 (-30)

100% less capital invested

Capital invested by funds: $135M → $0 (-$135M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 30

Holders
–
Holders Change
-30
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
30
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
WCMNY
Westchester Capital Management (New York)
New York
-$15.1M
2
WRBC
W.R. Berkley Corp
Connecticut
-$12.1M
3
FTCM
First Trust Capital Management
Illinois
-$12M
4
LA
Linden Advisors
New York
-$10.8M
5
RCM
Radcliffe Capital Management
Pennsylvania
-$7.79M

BIOS Hedge Fund Activity: Q4 2023 in Review

0 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) for Q4 2023, worth a combined $0 — down 100% from $135M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of BIOS and 0 opened new positions — a net loss of 30 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Westchester Capital Management (New York), exiting entirely with an estimated $15.1M sold.

  • 0 institutional investors held BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) as of Q4 2023, down from 30 in Q3 2023.
  • Funds reported $0 of BioPlus Acquisition Corp. Class A Ordinary Shares stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new BioPlus Acquisition Corp. Class A Ordinary Shares positions in Q4 2023 and 30 closed out, a net change of -30 holders.
  • The largest BioPlus Acquisition Corp. Class A Ordinary Shares seller in Q4 2023 was Westchester Capital Management (New York), an estimated $15.1M sold.

Based on aggregated 13F filings for Q4 2023.